Site - Investor Relations
Press Releases
Press Releases
Nov 13, 2019
Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of Repotrectinib in Pediatric Patients
Nov 12, 2019
Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of TPX-0046, a Novel RET/SRC Inhibitor
Nov 11, 2019
Nov 04, 2019
Oct 21, 2019
Sep 30, 2019
Sep 05, 2019
Sep 03, 2019
Sep 03, 2019
Aug 28, 2019
Pagination
Displaying 1 - 10 of 31